+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

InspireMD Inc (NSPR) - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 40 Pages
  • February 2022
  • GlobalData
  • ID: 4372875
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

InspireMD Inc (InspireMD) is a medical device company that develops and commercializes embolic prevention systems and neurovascular devices. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, acute myocardial infarction, and saphenous vein graft coronary intervention. It utilizes MicroNet stent platform technology to develop its products and offers solutions for various disease conditions such as stenting, embolic showers, restenosis and late stent thrombosis. The company markets its products through a network of distributors in Israel and Germany. InspireMD is headquartered in Tel Aviv, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company InspireMD Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

InspireMD Inc Company Overview
  • InspireMD Inc Company Snapshot
  • InspireMD Inc Pipeline Products and Ongoing Clinical Trials Overview
  • InspireMD Inc - Pipeline Analysis Overview
  • InspireMD Inc - Key Facts
  • InspireMD Inc - Major Products and Services
  • InspireMD Inc Pipeline Products by Development Stage
  • InspireMD Inc Ongoing Clinical Trials by Trial Status
  • InspireMD Inc Pipeline Products Overview
  • CGuard Embolic Prevention System
  • CGuard Embolic Prevention System Product Overview
  • CGuard Embolic Prevention System Clinical Trial
  • CGuard Prime
  • CGuard Prime Product Overview
  • Delivery System
  • Delivery System Product Overview
  • MGuard Drug Eluting Stent
  • MGuard Drug Eluting Stent Product Overview
  • Next Gen CGuard - 5F
  • Next Gen CGuard - 5F Product Overview
  • NGuard
  • NGuard Product Overview
  • PVGuard Peripheral
  • PVGuard Peripheral Product Overview
  • RGuard Renal
  • RGuard Renal Product Overview
  • InspireMD Inc - Key Competitors
  • InspireMD Inc - Key Employees
  • InspireMD Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • InspireMD Inc, Recent Developments
  • Nov 09, 2021: InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
  • Jun 02, 2021: InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
  • May 11, 2021: InspireMD Announces First Quarter 2021 Financial Results
  • Apr 29, 2021: InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
  • Mar 02, 2021: InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
  • May 05, 2020: InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
  • Mar 10, 2020: InspireMD announces fourth quarter and year-end 2019 financial results
  • Mar 03, 2020: InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
  • Jan 29, 2020: InspireMD announces successful live clinical case transmissions featuring CGuard EPS at the Leipzig Interventional Course (LINC) 2020
  • Jan 27, 2020: InspireMD’s CGuard Embolic Prevention System to be prominently featured in live case transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany

Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • InspireMD Inc Pipeline Products and Ongoing Clinical Trials Overview
  • InspireMD Inc Pipeline Products by Equipment Type
  • InspireMD Inc Pipeline Products by Indication
  • InspireMD Inc Ongoing Clinical Trials by Trial Status
  • InspireMD Inc, Key Facts
  • InspireMD Inc, Major Products and Services
  • InspireMD Inc Number of Pipeline Products by Development Stage
  • InspireMD Inc Pipeline Products Summary by Development Stage
  • InspireMD Inc Ongoing Clinical Trials by Trial Status
  • InspireMD Inc Ongoing Clinical Trials Summary
  • CGuard Embolic Prevention System - Product Status
  • CGuard Embolic Prevention System - Product Description
  • CGuard Embolic Prevention System - A Multicenter Italian Registry of Real World CAS with C-Guard Mesh Covered Stent: The IRONGUARD 2 Study
  • CGuard Embolic Prevention System - A Multicenter, Single-arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting
  • CGuard Embolic Prevention System - A Pivotal Study of the CGuard Carotid Stent System CARENET-III for Prevention of Stroke in Patients in the United States.
  • CGuard Embolic Prevention System - Carotid Artery Revascularization Using TransCarotid flow Reversal Cerebral Protection And CGUARD MicroNET-covered Embolic Prevention Stent System to Reduce Strokes in Patients with Symptoms or Signs of Cerebral Ischemia: TOP-GUARD Study
  • CGuard Embolic Prevention System - Long-term Outcomes of MicroNet-covered Stent Routine Use for Stroke Prevention in Symptomatic and Increased-risk Asymptomatic Carotid Stenosis Patients Requiring Revascularization by Neurovascular Team Decision: PARADIGM-EXTEND
  • CGuard Embolic Prevention System - OPTIMAl Endovascular Exclusion of High-risk Carotid Plaque Using the CGuard Stent in Patients with Symptoms or Signs of Carotid Stenosis-related Brain Injury: IVUS Controlled Investigator Initiated Multcentric Multi-specialty Study
  • CGuard Embolic Prevention System - Prospective Evaluation of All-comer Percutaneous Carotid Revascularization In Symptomatic and Increased-risk Asymptomatic Carotid Artery Stenosis
  • CGuard Embolic Prevention System - Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)
  • CGuard Embolic Prevention System - Prospective Observational Study of Procedures with MicroNet Covered Stent Use to Treat Increased Risk Lesions in Arterial Locations Beyond the Carotid Bifurcation - FLOW-Guard Study
  • CGuard Prime - Product Status
  • CGuard Prime - Product Description
  • Delivery System - Product Status
  • Delivery System - Product Description
  • MGuard Drug Eluting Stent - Product Status
  • MGuard Drug Eluting Stent - Product Description
  • Next Gen CGuard - 5F - Product Status
  • Next Gen CGuard - 5F - Product Description
  • NGuard - Product Status
  • NGuard - Product Description
  • PVGuard Peripheral - Product Status
  • PVGuard Peripheral - Product Description
  • RGuard Renal - Product Status
  • RGuard Renal - Product Description
  • InspireMD Inc, Key Employees
  • InspireMD Inc, Other Locations
  • InspireMD Inc, Subsidiaries
  • Glossary

List of Figures
  • InspireMD Inc Pipeline Products by Equipment Type
  • InspireMD Inc Pipeline Products by Development Stage
  • InspireMD Inc Ongoing Clinical Trials by Trial Status

Companies Mentioned

A selection of companies mentioned in this report includes:

  • InterCure Ltd
  • Etropal Ad
  • Bioiasis AD Sofia